Welcome to DailyUpdates Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 2 more day(s). To receive DailyUpdates by e-mail register here

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development

---

---

• Recommend DailyUpdates
• Other Therapeutic Channels
• UpdatesPlus
• Consultancy
• Modify Subscription
• Past Content
• Submit to DailyUpdates
• Contact

	If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work
Useful Links: Recommend DailyUpdates UpdatesPlus Consultancy Modify your subscription Search past content Submit a paper to DailyUpdates Contact LeadDiscovery	Today's journal articles Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate. Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial. Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know... New Clinical Trials No clinical trials today Previous Journal Entries Adenovirus Targeting to Prostate-specific Membrane Antigen through Virus-displayed Semi-random Peptide Library Screening. Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes. Structure - Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. IL-15R{alpha}-IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-infected Adults. Controlling Amyloid-beta Peptide(1-42) Oligomerization and Toxicity by Fluorinated Nanoparticles. Human Cord Blood-derived Endothelial Progenitor Cells and their Conditioned Media Exhibit Therapeutic Equivalence for Diabetic Wound Healing. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. 18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. A combination of DR5 agonistic mAb with gemcitabine targets pancreatic cancer stem cells, and results in long-term disease control in human pancreatic cancer model. In vivo angiogenesis imaging of solid tumors by {alpha}v{beta}3-targeted, dual-modality micellar nanoprobes.	Today's News Items AGENSYS, AN AFFILIATE OF ASTELLAS, ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL OF AGS-16M8F FOR RENAL CANCER Daiichi Sankyo Files for Approval to Manufacture and Market AMG 162 (Denosumab) in Japan Training Courses & Meetings No events listed Previous News Items MedImmune receives complete response letter on motavizumab For faster discovery, automatically organize PubMed results into categories